Novo Nordisk (NVO) Revenue Impact from Semaglutide at 75% in 2026
Published on Β· Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowMorgan Stanley downgraded Novo Nordisk A/S (NVO) to Underweight on September 11, 2026, citing that Semaglutide contributes roughly 75% of the company's revenue for 2026. The firm anticipates that this will drop to 59% by 2031 when the patent expires. Novo's stock is currently trading at a P/E ratio of 10.6 and has fallen 33% from its 52-week high, slipping an additional 2% after the downgrade. This information matters for investors because the shift in revenue sources post-patent expiration could significantly affect Novo's future earnings and valuation.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Morgan Stanley (MS)
Morgan Stanley is a leading global investment bank and wealth manager.
The Financials sector covers banks, insurers and capital-markets firms at the center of the economy.
Earlier MS news
- Marathon Petroleum (MPC) Price Target Raised to $453 by Morgan Stanley
- Valero (VLO) Soars 140%, Morgan Stanley Targets $411 Ahead
- Morgan Stanley Upgrades Shell (SHEL) to Overweight with New Price Target
- Trump Denies Access to MS NOW, CNN, Politico Journalists
- MS NOW Journalists Blocked from White House Amid Trump Ban
Understand this kind of story
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
Related News
Aeromexico Plans New US Flights After Washington Lifts Restrictions
Oct 19
SpaceX AI Computing Power Rental Driving Revenue Growth but Raising Costs
Oct 19
S&P 500 and Nasdaq Rise as AI Stocks Rebound Before Earnings
Oct 19
A&W (TSX:AW) Q3 Results Show Margin Squeeze Impact
Oct 18